Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 28 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
Mo | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
14.05. | Zentalis Pharmaceuticals GAAP EPS of -$0.67 misses by $0.04 | 1 | Seeking Alpha | ||
14.05. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
01.05. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 77 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
28.04. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.04. | Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
01.04. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 99 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
27.03. | Stifel maintains Buy on Zentalis stock with $9 target | 2 | Investing.com | ||
27.03. | H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy | 1 | Investing.com | ||
26.03. | Zentalis Pharmaceuticals GAAP EPS of -$2.33 beats by $0.13, revenue of $67.43M beats by $26.81M | 3 | Seeking Alpha | ||
26.03. | Zentalis Pharmaceuticals files $250M mixed securities shelf | 1 | Seeking Alpha | ||
26.03. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.03. | Zentalis Pharmaceuticals, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
26.03. | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | 116 | GlobeNewswire (Europe) | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part... ► Artikel lesen | |
25.03. | Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 | 1 | GlobeNewswire (USA) | ||
17.03. | H.C. Wainwright maintains $10 target on Zentalis stock | 1 | Investing.com | ||
17.03. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
15.03. | Zentalis Announces Updated Clinical Data From Part 1b Of DENALI Trial Of Azenosertib In PROC | 12 | RTTNews |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
MODERNA | 23,805 | +1,08 % | Kurs von Moderna steigt etwas (24,09 €) | Im US-amerikanischen Wertpapierhandel liegt das Wertpapier von Moderna gegenwärtig im Plus. Die Aktie notiert aktuell bei 24,09 Euro. Die Aktie von Moderna verzeichnet zur Stunde ein Kursplus von 4... ► Artikel lesen | |
VALNEVA | 2,732 | -0,15 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH 03.06.2025 / 14:27 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den... ► Artikel lesen | |
NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,437 | -2,02 % | Breaking News: NurExone gibt die Planung und Details der klinischen Humanstudie mit ExoPTEN bekannt! | ||
IMMUNITYBIO | 2,812 | +1,88 % | FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia | ||
ALDEYRA | 2,301 | -1,24 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
CARDIFF ONCOLOGY | 3,425 | +0,74 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 | - Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate - - The trial evaluated three doses... ► Artikel lesen | |
IOVANCE BIOTHERAPEUTICS | 1,798 | +0,21 % | Goldman Sachs bekräftigt Kaufempfehlung für Iovance-Aktie nach ASCO-Daten | ||
COHERUS ONCOLOGY | 0,738 | +2,08 % | Coherus BioSciences, Inc. (CHRS): A Bull Case Theory | ||
OCULAR THERAPEUTIX | 7,840 | -1,01 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
GUARDANT HEALTH | 42,760 | +1,38 % | Cathie Wood's ARK sells Palantir and Roblox, buys Veracyte and Guardant | ||
ESPERION | 1,082 | +1,50 % | Esperion Therapeutics, Inc. - 8-K, Current Report | ||
VOYAGER THERAPEUTICS | 3,174 | +2,59 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report |